Apple has officially reinstated the blood oxygen monitoring functionality on its flagship Apple Watch Series 9 and Ultra 2 models, resolving a technical limitation imposed by a previous legal injunction. The move restores the pulse oximetry sensor’s capabilities for U.S. consumers, ending a months-long period where the feature was disabled to comply with an International Trade Commission (ITC) ruling regarding patent infringement.
The Path Back to Pulse Oximetry
The return of the health-tracking feature marks a pivotal moment in Apple’s legal dispute with Masimo, a medical technology firm that accused the tech giant of misappropriating its light-based blood oxygen sensing technology. Following the ITC’s initial ban, Apple was forced to strip the functionality from its newest wearables to continue selling them in the United States. This restoration suggests a shift in the legal landscape or a technical workaround that satisfies regulatory requirements.
Impact on Series 9 and Ultra 2 Functionality
With the feature active, users of the Apple Watch Series 9 and Apple Watch Ultra 2 can once again measure the oxygen saturation (SpO2) of their blood directly from their wrist. This metric is essential for users monitoring respiratory health, athletic performance, and sleep quality. The restoration ensures that Apple’s premium hardware remains competitive in a market where health-centric data serves as a primary selling point for high-end smartwatches.
Strategic Implications for Apple Health
Apple’s ability to bring back blood oxygen monitoring reinforces its commitment to the “Health” ecosystem as a core pillar of its hardware strategy. By navigating the complexities of medical patent law, Apple maintains its trajectory of integrating clinical-grade sensors into consumer electronics. While the legal battle with Masimo may continue in various jurisdictions, the immediate availability of the sensor provides clarity for consumers looking to upgrade to the latest Apple Watch iterations.
